NASDAQ:LIAN LianBio (LIAN) Stock Price, News & Analysis $0.32 -0.03 (-8.28%) (As of 03/18/2024) Add Compare Share Share Today's Range$0.28▼$0.3550-Day Range$0.28▼$0.3352-Week Range$0.27▼$4.99Volume2.49 million shsAverage Volume1.04 million shsMarket Capitalization$34.47 millionP/E RatioN/ADividend YieldN/APrice Target$5.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartDividendEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartDividendEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get LianBio alerts: Email Address LianBio MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside1,571.9% Upside$5.33 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom $2.40 to ($0.86) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.70 out of 5 starsMedical Sector803rd out of 879 stocksBiotechnology Industry6th out of 9 stocks 3.0 Analyst's Opinion Consensus RatingLianBio has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 1 hold rating, and 1 sell rating.Amount of Analyst CoverageLianBio has received no research coverage in the past 90 days.Read more about LianBio's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for LIAN. Previous Next 0.0 Dividend Strength Dividend YieldLianBio does not currently pay a dividend.Dividend GrowthLianBio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LIAN. Previous Next 0.6 News and Social Media Coverage Search Interest1 people have searched for LIAN on MarketBeat in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, LianBio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.59% of the stock of LianBio is held by insiders.Percentage Held by Institutions74.85% of the stock of LianBio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about LianBio's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for LianBio are expected to decrease in the coming year, from $2.40 to ($0.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of LianBio is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of LianBio is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLianBio has a P/B Ratio of 0.12. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Freeport SocietyOperation Replace Biden is a GoLast night’s debate proved me right: Joe Biden will be replaced. I’ve been making this warning for months… and people laughed at me.Click here for my urgent election update. About LianBio Stock (NASDAQ:LIAN)LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.Read More LIAN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LIAN Stock News HeadlinesMay 10, 2024 | msn.comChina's Zeekr prices US IPO at top of range to raise $441 millionMay 9, 2024 | msn.comExclusive-China's Zeekr prices US IPO at top of range to raise $441 million, source saysJuly 8, 2024 | Paradigm Press (Ad)Biden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on August 19.March 15, 2024 | investorplace.comWhy Is LianBio (LIAN) Stock Moving Today?February 28, 2024 | globenewswire.comLianBio Announces Voluntarily Delisting from NasdaqFebruary 23, 2024 | seekingalpha.comWith No Cure In Sight, Drugs Firm LianBio Begins Exit StrategyFebruary 13, 2024 | markets.businessinsider.comLianBio Announces Wind Down Of Operations, Workforce Reduction; Stock Up In Pre-MarketFebruary 13, 2024 | marketwatch.comLianBio to Wind Down Operations, Declares Special DividendJuly 8, 2024 | Paradigm Press (Ad)Biden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on August 19.February 13, 2024 | marketwatch.comLianBio Shares Gain After Co Announces Plans to Wind DownFebruary 13, 2024 | finance.yahoo.comLianBio Announces Completion of Strategic ReviewJanuary 3, 2024 | markets.businessinsider.comB of A Securities Downgrades LianBio: Here's What You Need To KnowDecember 26, 2023 | markets.businessinsider.comNanobiotix Partner LianBio Assigns Its Development and Commercialization Rights for NBTXR3 in China and Other Asian MarketsDecember 26, 2023 | finance.yahoo.comLianBio Enters into Agreement Assigning its Rights for NBTXR3 in China and Other Asian MarketsDecember 20, 2023 | realmoney.thestreet.comInterest Is Growing for Smaller, More Speculative NamesDecember 20, 2023 | finance.yahoo.comLianBio Announces Departure of Chief Financial OfficerDecember 19, 2023 | marketwatch.comLianBio Names Stone as Interim CEO as Wang ResignsDecember 19, 2023 | finance.yahoo.comLianBio Announces Departure of Chief Executive OfficerSee More Headlines Receive LIAN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LianBio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/27/2023Today7/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:LIAN CUSIPN/A CIK1831283 Webwww.lianbio.com Phone609-486-2308FaxN/AEmployees163Year FoundedN/APrice Target and Rating Average Stock Price Target$5.33 High Stock Price Target$9.00 Low Stock Price Target$3.00 Potential Upside/Downside+1,571.9%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.81) Trailing P/E RatioN/A Forward P/E Ratio0.13 P/E GrowthN/ANet Income$-110,290,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-33.17% Return on Assets-30.19% Debt Debt-to-Equity RatioN/A Current Ratio10.06 Quick Ratio10.06 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.71 per share Price / Book0.12Miscellaneous Outstanding Shares108,063,000Free Float99,861,000Market Cap$34.47 million OptionableNot Optionable Beta0.23 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Konstantin Poukalov (Age 40)Founder & Executive Chairman Mr. Adam Leo Stone (Age 43)Interim CEO & Director Ms. Ehong GuInterim CFO, VP & Head of Global FinanceJi ChenSenior VP & General CounselMs. Brianne Jahn (Age 38)Chief Business Officer Comp: $697.47kDr. Michael Humphries M.D.Chief Scientific AdvisorMr. Levvy Lv D. EngSenior VP & Global Head of DevelopmentMore ExecutivesKey CompetitorsPHAXIAM TherapeuticsNASDAQ:PHXMKaleido BiosciencesNASDAQ:KLDOPolarityTENASDAQ:PTEIQ9 Meters BiopharmaNASDAQ:NMTRHumanigenNASDAQ:HGENView All Competitors LIAN Stock Analysis - Frequently Asked Questions How have LIAN shares performed this year? LianBio's stock was trading at $4.47 at the beginning of the year. Since then, LIAN stock has decreased by 92.9% and is now trading at $0.3190. View the best growth stocks for 2024 here. How were LianBio's earnings last quarter? LianBio (NASDAQ:LIAN) issued its earnings results on Monday, March, 27th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.10. When did LianBio IPO? LianBio (LIAN) raised $325 million in an initial public offering (IPO) on the week of November 1st 2021. The company issued 20,300,000 shares at a price of $16.00 per share. Goldman Sachs, Jefferies and BofA Securities served as the underwriters for the IPO. How do I buy shares of LianBio? Shares of LIAN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LIAN) was last updated on 7/8/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredI’m giving you the name of this investment for freeThis key unlocks a new pathway to wealth that has been kept hidden from you for decades. In my new documen...Porter & Company | SponsoredOperation Replace Biden is a GoLast night’s debate proved me right: Joe Biden will be replaced. I’ve been making this warning for months… ...The Freeport Society | SponsoredBiden to drop out; finish out his term?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredObama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In f...Stansberry Research | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredGrab Your Free Bitcoin Today!And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LianBio Please log in to your account or sign up in order to add this asset to your watchlist. Share LianBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LIAN Stock Alerts